Business Services
Medical
Research And Development

Altimmune

$2.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.29 (-8.73%) Today
-$0.05 (-1.65%) After Hours

Why Robinhood?

You can buy or sell Altimmune and other stocks, options, ETFs, and crypto commission-free!

About

Altimmune, Inc. Common Stock, also called Altimmune, is a clinical stage company, which engages in the research and development of immunotherapeutic products. Read More Its portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Employees
30
Headquarters
Gaithersburg, Maryland
Founded
1997
Market Cap
5.73M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
675.20K
High Today
$3.31
Low Today
$2.98
Open Price
$3.16
Volume
1.41M
52 Week High
$49.20
52 Week Low
$1.70

Collections

Business Services
Medical
Research And Development
Cancer Prevention
Health
US
North America

News

Yahoo FinanceMar 19

Altimmune's Flu Shot Study: What You Need To Know

Altimmune Inc (NASDAQ: ALT), which develops immunotherapies and vaccines, is seeing its stock surge on 15 times its average volume after the company reported the results of a midstage study of its lead candidate NasoVAX. What Happened The nanocap biotech company said Tuesday that additional data from a Phase 2 extension study of its NasoVAX, an intranasal influenza vaccine candidate, showed that 100 percent of the evaluated subjects remained seroprotected. The seroconversion rate was unchanged more than ...

532
Seeking AlphaMar 19

Sorrento Therapeutics and Altimmune among healthcare gainers; Selecta Biosciences and AquaBounty Technologies among losers - Altimmune, Inc. (NASDAQ:ALT)

456
Associated PressMar 19

Altimmune Announces Positive Results from NasoVAX Extension Study

Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100% of the evaluated subjects remained serop...

735

Earnings

-$3.60
-$2.43
-$1.25
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 27, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.